Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole

被引：35
作者：
Moriyama B. [1 ]
Kadri S. [2 ]
Henning S.A. [1 ]
Danner R.L. [2 ]
Walsh T.J. [3 ]
Penzak S.R. [4 ]
机构：
[1] Pharmacy Department, NIH Clinical Center, 10 Center Drive, Bethesda, 20892, MD
[2] Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD
[3] Transplantation-Oncology Infectious Diseases Program, Department of Medicine Pediatrics and Microbiology and Infectious Diseases, Weill Cornell Medical Center of Cornell University, New York, NY
[4] Department of Pharmacotherapy, University of North Texas System College of Pharmacy, Fort Worth, TX
来源：
Current Fungal Infection Reports | 2015年 / 9卷 / 2期
基金：
美国国家卫生研究院;
关键词：
CYP2C19; Pharmacogenomics; Pharmacokinetics; Voriconazole;
D O I：
10.1007/s12281-015-0219-0
中图分类号：
学科分类号：
摘要：
Voriconazole is an antifungal triazole that is the first-line agent for treatment of invasive aspergillosis. It is metabolized by CYP2C19, CYP2C9, and CYP3A4 and demonstrates wide interpatient variability in serum concentrations. Polymorphisms in CYP2C19 contribute to variability in voriconazole pharmacokinetics. Here, evidence is examined for the use of voriconazole therapeutic drug monitoring (TDM) and the role of CYP2C19 genotyping in voriconazole dosing. The majority of studies exploring the impact of voriconazole TDM on efficacy and safety have found TDM to be beneficial. However, most of these studies are observational, with only one being a randomized controlled trial. High-volume multicenter randomized controlled trials of TDM are currently not available to support definitive guidelines. There is a significant relationship in healthy volunteers between CYP2C19 genotype and voriconazole pharmacokinetics, but this association is markedly less visible in actual patients. While CYP2C19 genotype data may explain variability of voriconazole serum levels, they alone are not sufficient to guide initial dosing. The timeliness of availability of CYP2C19 genotype data in treatment of individual patients also remains challenging. Additional studies are needed before implementation of CYP2C19 genotyping for voriconazole dosing into routine clinical care. ©Springer Science+Business Media New York (outside the USA) 2015.
引用
收藏
页码：74 / 87
页数：13
相关论文
共 97 条
[1]  
Vfend (Voriconazole), (2014)
[2]  
Walsh T.J., Anaissie E.J., Denning D.W., Et al., Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis, 46, pp. 327-360, (2008)
[3]  
Pappas P.G., Kauffman C.A., Es D., Et al., Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, pp. 503-535, (2009)
[4]  
Theuretzbacher U., Ihle F., Derendorf H., Pharmacokinetic/ pharmacodynamic profile of voriconazole, Clin Pharmacokinet, 45, pp. 649-663, (2006)
[5]  
Andes D., Pascual A., Marchetti O., Antifungal therapeutic drug monitoring: Established and emerging indications, Antimicrob Agents Chemother, 53, pp. 24-34, (2009)
[6]  
Geist M.J., Egerer G., Burhenne J., Mikus G., Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype, Antimicrob Agents Chemother, 50, pp. 3227-3228, (2006)
[7]  
Weiss J., Ten Hoevel M.M., Burhenne J., Et al., CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole, J Clin Pharmacol, 49, pp. 196-204, (2009)
[8]  
Lee S., Kim B.H., Nam W.S., Et al., Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers, J Clin Pharmacol, 52, pp. 195-203, (2012)
[9]  
Purkins L., Wood N., Ghahramani P., Greenhalgh K., Allen M.J., Kleinermans D., Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens, Antimicrob Agents Chemother, 46, pp. 2546-2553, (2002)
[10]  
Wang L., McLeod H.L., Weinshilboum R.M., Genomics and drug response, N Engl J Med, 364, pp. 1144-1153, (2011)
12345678910